Plaintiff
59 cases as plaintiff.
Watchlist
Email-only, free, anonymous. We'll notify you when Jazz Pharmaceuticals, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Fourth Jazz Complaint re-asserting U.S. 8,731,963 after FDA required Avadel to file a Paragraph IV certification. Avadel counterclaimed for non-infringement, invalidity, delisting, and Sherman Act monopolization. The case was dismissed by stipulation on March 7, 2023.
Fourth Jazz complaint/antitrust case involving Jazz's listing of the '963 (REMS) patent and Avadel's Sherman Act counterclaims. Jazz moved to stay pending final resolution of the validity of U.S. Patent No. 11,147,782. Dismissed with prejudice on October 27, 2025 pursuant to settlement.
Patent infringement action involving Jazz Pharmaceuticals entities and Avadel entities; resolved in the same October 2025 global settlement and stipulation of dismissal with prejudice entered October 27, 2025.
First Jazz Complaint in D. Del. over Avadel's FT218/LUMRYZ. The consolidated action asserted five patents, including U.S. 8,731,963. The court held the '963 claims directed to systems, not methods, and ordered Jazz to request delisting from the Orange Book; on March 7, 2023, the '963 infringement claims and related counterclaims were dismissed by stipulation. Other patents, including U.S. 10,758,488 and 11,147,782, proceeded to a 2024 jury verdict.
Jazz-side Delaware action in the Avadel–Jazz once-nightly sodium oxybate dispute. The '986 patent appeared on the patent lists in connection with Avadel's counterclaims and inequitable-conduct/derivation allegations concerning Flamel's '321 application and Jazz's '079/'782 patents. The case was resolved by the October 2025 settlement and dismissed with prejudice on 2025-10-27.
Lead Hatch-Waxman/Lumryz case reported for US 10,736,866; the case went to jury trial in 2024 and was terminated on 2025-10-27.
Patent infringement action by Jazz Pharmaceuticals against Avadel CNS Pharmaceuticals concerning sodium oxybate/LUMRYZ; consolidated with related actions and resolved by a global settlement and stipulation of dismissal with prejudice entered October 27, 2025.
DrugPatentWatch lists the '400 patent in this Avadel matter; the exact case number and whether the '400 patent was actually asserted could not be independently confirmed. It is listed as terminated Oct 27, 2025.
Jazz entities sued Mallinckrodt Inc. in D.N.J. involving the '106 patent. The case was closed and later settled.
Terminated June 15, 2018.
Jazz Pharmaceuticals, Inc. et al. sued Ascent Pharmaceuticals, Inc. in E.D.N.Y. involving U.S. Patent 9,050,302. Jazz voluntarily dismissed the action on Aug. 30, 2017.
Jazz Pharmaceuticals, Inc. sued Amneal Pharmaceuticals LLC in D.N.J., asserting U.S. Patent 9,050,302 among others. The case was part of the consolidated Xyrem ANDA litigation before Judge Esther Salas and is closed.
ANDA Hatch-Waxman action by Jazz Pharmaceuticals and others against Lupin Ltd. and others involving Xyrem and US 7,765,107. Complaint filed September 1, 2015; case terminated January 15, 2016.
Jazz Pharmaceuticals, Inc. et al. sued Lupin entities in D.N.J. involving the '106 patent. The case was closed and later settled June 12, 2018 per Hagens Berman complaint; docket noted termination Jan. 15, 2016 per L. Civ. R. 11.2 certification.
Jazz Pharmaceuticals and Jazz Pharmaceuticals Ireland sued Wockhardt entities in D.N.J. over ANDA No. 207526. Wockhardt filed counterclaims for declaratory judgment of invalidity/non-infringement of the '988 patent and others, and later settled before the Federal Circuit decision.
Resolved by a stipulation/consent judgment of dismissal. Wockhardt admitted the ANDA filing was a technical act of infringement of the asserted patents, expressly including 8,772,306, and was enjoined except as permitted by the April 18, 2016 license agreement.
The '306 patent was asserted; Roxane moved to dismiss the '306 claims on §101 subject-matter eligibility, which the court administratively terminated and stayed discovery on pending IPR. The case was consolidated with Roxane's '302 case on Mar 24, 2016 and settled in April 2017.
DrugPatentWatch lists 8,324,275 as asserted in Jazz Pharmaceuticals v. Roxane Laboratories; the case was resolved via the April 2017 Jazz–Roxane settlement.
Hatch-Waxman ANDA patent infringement action in the District of New Jersey. The multi-patent Xyrem complaint included US 7,668,730 and also asserted the '059, '988, '182, and '963 patents. The case was resolved short of trial and closed.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.
Jazz Pharmaceuticals sued Par Pharmaceutical in D.N.J. over an ANDA for sodium oxybate oral solution. The case was consolidated with Jazz v. Amneal, No. 2:13-cv-00391, with the '988 patent among the patents-in-suit.
ANDA Hatch-Waxman action by Jazz Pharmaceuticals against Par Pharmaceuticals involving Xyrem and US 7,765,107. Par's Paragraph IV notice was dated November 20, 2013; the case later settled on January 9, 2018 with an authorized-generic license.
Consolidated D.N.J. Xyrem action in which the '306 patent was folded in and construed in the court's Markman decision. Terminated by Amneal settlement on Oct 15, 2018.
Jazz asserted seven Xyrem patents, including the '275 patent; Amneal's answer included Count VII: Infringement of the '275 Patent. Consolidated into the D.N.J. Xyrem ANDA proceedings and ultimately resolved by settlement.
Jazz sued Roxane Laboratories (later Hikma/West-Ward) asserting the '650 patent. The case was consolidated with 2:10-cv-06108 and 2:12-cv-07459 in April 2013, and the consolidated case settled April 5, 2017, granting Hikma/West-Ward an authorized generic of Xyrem beginning Jan. 1, 2023.
Hatch-Waxman ANDA suit filed by Jazz Pharmaceuticals against Roxane Laboratories concerning U.S. 7,895,059. The case was consolidated with lead action 2:10-cv-06108 and settled in April 2017.
Lead/first ANDA Hatch-Waxman case filed by Jazz Pharmaceuticals against Roxane Laboratories. The complaint expressly asserted US 7,765,107 along with other patents ('889, '219, '730, '106); the '107 claims were later invalidated via IPR2015-00547.
Lead Hatch-Waxman action asserting the '219 patent against Roxane; consolidated with several related Roxane actions. Claim construction issued 2012-09-14 and the case settled before trial.
Federal Circuit appeal from the PTAB IPR decision on U.S. 8,589,182. The court affirmed, holding the FDA Advisory Committee materials were a publicly accessible printed publication and proper prior art; the decision disposed of the family patents together.
Related appeal from IPR2015-01903 (Jazz/Par appeal). The parties settled during appeal, and on January 9, 2018, Jazz entered a settlement with Par resolving the district court and IPR matters.
D.N.J. Hatch-Waxman/ANDA litigation over Xyrem. Jazz's mandatory notices in IPR2015-01903 identify the '963 patent as asserted in this action.
D.N.J. Hatch-Waxman/ANDA litigation over Xyrem. Jazz's mandatory notices in IPR2015-01903 identify the '963 patent as asserted in this action.
D.N.J. Hatch-Waxman/ANDA litigation over Xyrem. Jazz identified this action as concerning patents related to the '963 patent in its mandatory notices in IPR2015-01903.
Jazz Pharmaceuticals filed a D.N.J. ANDA action against Watson Laboratories concerning ANDA No. 204952. The case was consolidated into No. 2:13-cv-00391, with the '988 patent among the patents-in-suit.
This case appears on the '988 patent litigation docket, but the narrative could not independently verify the defendants, filing date, or outcome.
Hatch-Waxman ANDA suit filed by Jazz Pharmaceuticals against Par Pharmaceutical. The case was consolidated under 2:13-cv-0391 and settled on January 9, 2018.
Hatch-Waxman ANDA suit listed as related litigation involving Jazz Pharmaceuticals and Wockhardt Bio AG. Wockhardt's paragraph IV notices were dated June 5, 2015 and November 24, 2015.
Jazz sued Amneal over sodium oxybate ANDA No. 203631; Amneal's counterclaims expressly asserted that each claim of the '426 patent is invalid, confirming '426 was in suit. The outcome was not confirmed in the retrieved sources; the broader Jazz/Amneal Xyrem family was ultimately settled, but the '426 disposition specifically is unverified.
The '306 patent was asserted against Lupin. The case settled on June 12, 2018, as described in antitrust complaints.
One of the consolidated D.N.J. Xyrem ANDA actions against Ranbaxy. A consolidation stipulation recites that this action alleged infringement of a patent list including US 6,780,889; it was consolidated with related Xyrem actions and resolved/terminated in the 2015-2018 window.
D.N.J. Xyrem ANDA action against Watson, consolidated with the Ranbaxy and Amneal Xyrem actions for a 500 mg/ml generic sodium oxybate oral solution. The narrative identifies it among the Hatch-Waxman suits filed by Jazz on US 6,780,889; it was resolved/terminated in the 2015-2018 window.
Related Amneal action consolidated into the Jazz v. Amneal '219 patent litigation.
Related Par action consolidated into the Jazz v. Amneal '219 patent litigation.
Related Ranbaxy action listed on the '219 Google Patents litigation page and consolidated; settled pre-trial.
Related Watson action listed on the '219 Google Patents litigation page and consolidated; settled pre-trial.
Lumryz/FT218 litigation; trial record identifies the '219 patent as a Jazz patent. Actively litigated in 2023; final judgment not confirmed.
The '275 patent appears in the list of patents-in-suit recited in the consolidated D.N.J. Watson pleadings; resolved by settlement. Consolidated with 14-6151 and 15-187.
Filed after Amneal's Dec. 10, 2012 Paragraph IV notice. Amneal counterclaimed for non-infringement/invalidity of the '650 patent, inequitable conduct, and prosecution laches; the case settled.
Filed after Par's Nov. 20, 2013 Paragraph IV notice; settled.
Filed after Ranbaxy's June 3, 2014 Paragraph IV notice; settled. The narrative lists this docket and/or 2:14-cv-04467 for the Ranbaxy suit.
Filed after Watson's Oct. 29, 2014 Paragraph IV notice regarding ANDA No. 204952 (500 mg/mL sodium oxybate). The complaint names the '650 patent as a patent-in-suit; settled.
Filed after Wockhardt's June 8, 2015 Paragraph IV notice; settled.
Filed after Lupin's July 23, 2015 Paragraph IV notice. The complaint confirms the '650 patent as a patent-in-suit; settled.
Filed after Ascent's June 14, 2017 Paragraph IV notice regarding ANDA No. 210523 (500 mg/mL sodium oxybate). The complaint names the '650 patent; settled per overall narrative.
Party name not retrieved; listed as Xyrem-family litigation.
Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.
Related Jazz v. Roxane action listed for the ’506 patent family and consolidated into 2:10-cv-06108. Resolved as part of the Roxane settlement.
Lupin action consolidated into the Jazz v. Amneal consolidated litigation, 2:13-cv-00391.
Consolidated Xyrem patent litigation in the District of New Jersey into which numerous ANDA cases, including Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Ltd. (2:14-cv-04467), were consolidated for all purposes. The consolidation orders confirm the '203 patent litigation stream flowed into this broader case.